Theratechnologies Inc T.TH

POC in humans has been acheived is that it

[Trogarzon]

“We have eagerly awaited the updated analysis from Parts 1 and 2 of the Phase 1 trial, as it will provide our first evidence of the long-term effects of sudocetaxel zendusortide in patients with solid tumors,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies.

[palinc2000]

Of couse !!!!!What else could explain thid Buying frenzy in this morning s trading!

[Trogarzon]

Is this genuine good news or is it timed to get more votes before AGM.  Will it be used to justify another dilution after the AGM.  It's unclear until someone starts buying.

[SPCEO1]

The data they will present is not focused on efficacy but on safety, PK, etc. and on long term info on the lower 300 mg dose. So, I would not expect any market moving info from this presentation but maybe somethign that gives us a little more reason to hope regarding the eventual release of the key part 3 results.

[Trogarzon]

Takes the focus off the Ongoing concern sh.t for a while at least.  Looking at Trump media with it's 6.5B market cap... less sales than Thera and huge losses.. go figure what drives stock prices lately.  Oh I forgot the 60k Turdcoins.... Charlie said it... turds are hot now.

[Saurus100]

Rusty, With all due respect, the press release's title and content say, "It will present long-term efficacy, safety, and pharmacokinetic (PK) data." Therefore, I expect new information regarding long-term efficacy, aren't you? I agree with all of you; we have been disappointed many times... But when you say the data they will present is not focused on efficacy, is that a feeling

[palinc2000]

They will report data on Part 1 and Part 2 of Phase 1   The important Phase  part 3 data ( dose optimization part) are not expected to be known or disclosed at the time of thr Poster Presentation

[SPCEO1]

I have not spoken with management. Just my expectation that if they had really impressive, market moving efficacy data they would have already announced it. If they had great data, it would be in their interests and ours for them to shout it from the mountaintop as soonas they could, push the share price up and maybe raise money of it to at elast pay the $40 million tracnhe of MArathon debt off in

[Joemare]

I believe they can only annonce data once ASCO releases abstracts.

[SPCEO1]

That is correct but they could have made an announcement of any really good data before committing to the conference. And given how badly things have been going for THTX, an early announcement might have been quite tempting if they really had fantastic info to report. We have to hope there is something that is intriguing in whatever they release at the conference that increases our hope they may

[Trogarzon]

That stuff always leaks and by looks of it it's nothing to get too excited about.  They need to show very good efficcaity and I'm not sure they can afford to do it or convince someone else to do it for them.  Egrifta works in Nash and they coul'nt even do that in the last 3 years.  Anyway lets hope it works.

[Lee430]

If I correctly recall Dr. Winer during a video presentation for Thera was definitely encouraged about TH1902 potential and mentioned one of his patients that had dropped out of the trial for personal reasons yet who’s cancer was amazingly not progressing, I believe he attributed that to some of the other benefits of TH1902, thinking he mentioned the patient was due soon for another follow exam at

[Mannequin]

Yes I was impressed as well during that video call.

[scarlet1967]

    Just wanted to clarify the fact that 300mg/m2 is the higher dose level in part 3 of phase1(the second group of the patients will be dosed at that level)! Therefore what ever this new presentation will be revealing almost will be relevant as the dosage is (despite the different intervals, weekly versus previously every 3 weeks) similar to the ongoing clinical trial. 

[Mannequin]

It seems to me that maybe they have seen something but really have not been able to properly isolate the dose and they are fine tuning it. Is this number of patients enough to get into a Ph2  

[Trogarzon]

Hope so, they spent 50M of borrowed money @ 15% that cost 50% dilution and 95% loss of shareholder value for a maybe they saw something but could'nt isolate it.  Ok lets vote them back... shish....

[scarlet1967]

To me it seems like they are trying to link the new optimized dosing and its results with previous trial/trial's results. There is still a part 4 for this new trial design. Could they alter it again and go straight to phase2 based on sufficient data? I believe so!  

[Trogarzon]

That would be awsome... Blackjack scenario...

[Qwerty54321]

I would really caution that this is them just doing what responsible trial sponsors should do and putting out their complete data set. It doesn't point necessarily to any meaningful advancement of the program. That may be under-selling the actual data content but it seems like a reasonable guess to me.  

[Trogarzon]

Last trading day before the vote deadline of May 5th.  This was the last day to try influence the vote outcome. 

[Trogarzon]

Still no in person AGM.. the Covid19 has been over for long time now.. but they only need to call couple of clients now since last october legacy shareholder liquidation.

[Qwerty54321]

I do think SPCEO is right. I can't see any significant efficacy update, I can't actually see how any dial moving new data could have arisen. In fact I'd just put these posters into the box-ticking category. They are just doing what any responsible clinical program would/should do in making their long term data publically available. The only real hope for the cancer program seems to